Skip to main content
Figure 5 | Journal of Translational Medicine

Figure 5

From: Targeting Cdc42 with the small molecule drug AZA197 suppresses primary colon cancer growth and prolongs survival in a preclinical mouse xenograft model by downregulation of PAK1 activity

Figure 5

Analysis of AZA197-signal transduction effectors in SW620 colon cancer cells. A Cdc42 levels were not changed in SW620 cells treated with AZA197 compared to untreated cells. Means of 3 independent experiments are shown. B,C Analysis of PAK1 (B) and ERK (C) phosphorylation in SW620 colon cancer cells after AZA197 treatment. Representative Western blot images and quantification of immunoblots stained with PAK1, phospho-PAK1/2 (pPAK) and ERK, phospho-ERK (pERK) antibodies before and after treatment with 2, 5, and 10 μM AZA197 for 24 h. Cdc42 blockade reduces PAK1 and ERK phosphorylation in SW620 cells (mean of 3 independent experiments) without affecting total protein levels. *, significantly different from control. D Analysis of CyclinD1 expression in SW620 colon cancer cells following AZA197 treatment. Representative Western blot images and quantification of immunoblots stained with CyclinD1 antibody before and after treatment with 2, 5, and 10 μM AZA197 for 24 h. CyclinD1 levels were reduced following AZA197 treatment of SW620 cells (mean of three independent experiments). LC, loading control; SP, specific protein; *, significantly different from control.

Back to article page